A second-generation anti-CD40L monoclonal antibody suppresses multiple sclerosis (MS) disease activity on MRI to an uncommonly high degree, new trial data suggested.
Researchers found a near absence of new brain lesions at 48 weeks in patients on the highest dose. At this level of disease suppression, there was no evidence of increased infection risk, which investigators said might relate to its mechanism of action. In addition, there were no thrombotic events, which is what defeated a first-generation drug in this same class.
The findings were presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2024 Annual Meeting.
Learn More: https://www.medscape.com/viewarticle/multiple-sclerosis-med-nearly-eliminates-disease-activity-2024a1000aio
